Nephron Pharmaceuticals Announces CEO Transition, Appoints Haywood Miller as Interim Chief Executive
Nephron LLC and its subsidiaries (“Nephron” or the “Company”) have announced a leadership transition, with Lou Kennedy departing from her position as Chief Executive Officer and Haywood Miller appointed as Interim CEO, effective immediately. The change comes as the pharmaceutical manufacturer continues to advance its business transformation strategy, strengthen operations, and pursue long-term growth opportunities.
The company said it continues to receive support from its secured lenders, who remain confident in its transformation plans, growth priorities, established customer relationships, and manufacturing capabilities. Nephron emphasized that its immediate priorities remain unchanged, including maintaining operational stability and delivering safe, effective medications to healthcare providers and patients.
Richard Shinder, Nephron’s independent manager, thanked Kennedy for her leadership and years of service to the company. He also welcomed Miller, citing his operational expertise and familiarity with Nephron’s business as important assets as the organization moves forward with its transformation and growth initiatives.
The leadership transition is intended to maintain continuity across the company’s operations while reinforcing its focus on manufacturing performance, product quality, regulatory compliance, and customer service.
Haywood Miller Brings More Than 30 Years of Industry Experience
Miller brings more than three decades of leadership experience across pharmaceutical manufacturing and the broader healthcare industry. His previous advisory work with Nephron has also provided him with an understanding of the company’s operations, business priorities, and strategic challenges.
Over the past several months, Miller has served Nephron in an advisory capacity as a Managing Director at Berkeley Research Group. His familiarity with the business is expected to support a smooth transition into the interim leadership role and help the company continue executing its operational and commercial priorities.
As Interim CEO, Miller will work closely with Nephron’s leadership team to strengthen business operations, support investment in the company and its employees, and maintain the quality and reliability standards expected by customers.
His responsibilities will include helping advance the company’s transformation strategy while preserving the operational capabilities and customer relationships that underpin its pharmaceutical manufacturing business.
Nephron operates in an industry where consistent manufacturing performance, product quality, regulatory compliance, and reliable supply are essential. Leadership continuity is therefore particularly important in ensuring that strategic changes do not disrupt production activities or the delivery of medicines to healthcare providers.
Miller’s previous involvement with Nephron may also provide continuity in decision-making as the company works to improve operations and pursue its longer-term objectives.
Company Reaffirms Commitment to Transformation and Growth
Nephron said its secured lenders continue to support the company as it enters this next phase of leadership. According to the company, the lenders share confidence in its transformation strategy, growth priorities, customer relationships, and manufacturing footprint.
This support comes as Nephron continues to focus on strengthening its business and positioning its operations for sustainable growth.
The company’s transformation priorities include improving operational effectiveness, investing in its business and workforce, and maintaining the manufacturing standards necessary to serve healthcare providers reliably.
While the leadership announcement represents a significant organizational change, Nephron has stated that its core business priorities remain in place. The company intends to continue serving customers while working to strengthen its operational foundation and pursue growth opportunities.
Richard Shinder said Miller’s combination of operational expertise and knowledge of Nephron made him well suited to lead the company through its ongoing transformation.
Shinder also acknowledged Kennedy’s contributions, recognizing her leadership and long-standing service to the organization.
The company did not provide additional details regarding Kennedy’s departure or outline a timetable for appointing a permanent CEO in the announcement.
Haywood Miller Highlights Nephron’s Manufacturing Strengths
Miller said Nephron has an established foundation built on its employees, trusted customer relationships, and manufacturing capabilities. He expressed confidence in the opportunities available to the company and emphasized the importance of building on these strengths.
In his new role, Miller plans to work alongside the leadership team to advance the company’s transformation and growth strategy while maintaining its commitment to supplying high-quality medicines.
He also highlighted the importance of remaining a dependable source of medications for healthcare providers nationwide.
Nephron’s established customer relationships and manufacturing infrastructure represent important components of its business. Maintaining consistent product availability and reliable service will remain central to the company’s efforts as it moves through the leadership transition.
The company’s focus on its workforce is also expected to remain important. Investments in employees, operational capabilities, and manufacturing processes can help pharmaceutical manufacturers maintain consistent standards while responding to evolving customer requirements.
Although the company has not disclosed specific new investment commitments or detailed operational targets as part of the announcement, Miller’s stated priorities include strengthening operations and investing in both the business and its people.
Operational Continuity Remains a Priority
Nephron has taken steps to support an orderly leadership transition and maintain continuity across its business functions.
The company confirmed that manufacturing, compliance, quality, supply, and customer relationships remain areas of focus during the change. It also stated that operations continue as usual.
Maintaining continuity in these areas is particularly important for pharmaceutical manufacturers, where interruptions to production or distribution can affect healthcare providers and the patients who depend on their products.
Quality systems and regulatory compliance also remain essential to pharmaceutical manufacturing. Nephron’s commitment to maintaining established standards is intended to ensure that the leadership transition does not compromise the reliability of its products or services.
The company has emphasized that it will continue delivering safe and effective medications while advancing its transformation strategy. Its immediate approach combines operational continuity with a focus on strengthening the business and pursuing growth opportunities.
Outlook: Nephron Moves Forward Under Interim Leadership
The appointment of Haywood Miller marks a new leadership phase for Nephron Pharmaceuticals as the company continues its efforts to improve operations and execute its business transformation strategy.
Miller’s more than 30 years of experience in pharmaceutical manufacturing and healthcare, together with his recent advisory work with Nephron, provides familiarity with the organization as he assumes the interim position.
The company has reiterated that support from its secured lenders, established customer relationships, manufacturing capabilities, and experienced workforce remain important elements of its business foundation.
In the near term, Nephron’s priorities include maintaining stable manufacturing and supply operations, upholding product quality and compliance standards, investing in its people and business, and continuing to serve healthcare providers nationwide.
While the company has not announced further details about its long-term executive succession plans, it has indicated that its operations and strategic priorities will continue during the transition.
The leadership change therefore represents an organizational shift at a time when Nephron remains focused on operational reliability, business transformation, and sustainable growth in the pharmaceutical manufacturing sector.
